EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
Status:
RECRUITING
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 \[ERAP1\] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.